Literature DB >> 511954

Specific cellular defects in patients with Fanconi anemia.

R Weksberg, M Buchwald, P Sargent, M W Thompson, L Siminovitch.   

Abstract

Measurements of plating efficiency, accumulation of metaphases and generation times have shown that fibroblast from patients with Fanconi anemia (FA) have decreased probability of completing a further division after successful mitosis. Thus FA cells show decreased growth rates and increased generation times. We have also measured the survival of FA fibroblasts and lymphoblasts after treatment with a variety of mutagens. All FA cells show an increased sensitivity to drugs such as MMC and psoralen plus long wave length UV which cause DNA interstrand crosslinks. FA strains show varying degrees of sensitivity to these drugs and the extent of this sensitivity seems to be characteristic of each patient. FA cells are equal to controls in their sensitivity to other alkylating agents such as ethyl methane sulfonate, N-methyl-N1-nitro-N-nitrosoguanidine and actinomycin D. Both the decreased growth and increased drug sensitivity may result from defect in DNA replication or repair.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 511954     DOI: 10.1002/jcp.1041010211

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  18 in total

1.  Partial complementation of the Fanconi anemia defect upon transfection by heterologous DNA. Phenotypic dissociation of chromosomal and cellular hypersensitivity to DNA cross-linking agents.

Authors:  C Diatloff-Zito; F Rosselli; J Heddle; E Moustacchi
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

2.  Abnormal response to DNA crosslinking agents of Fanconi anemia fibroblasts can be corrected by transfection with normal human DNA.

Authors:  C Diatloff-Zito; D Papadopoulo; D Averbeck; E Moustacchi
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

Review 3.  TNF-α, a good or bad factor in hematological diseases?

Authors:  Tian Tian; Min Wang; Daoxin Ma
Journal:  Stem Cell Investig       Date:  2014-06-01

4.  Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. I. Involvement of interleukin-6.

Authors:  F Rosselli; J Sanceau; J Wietzerbin; E Moustacchi
Journal:  Hum Genet       Date:  1992-04       Impact factor: 4.132

5.  Microphthalmia transcription factor expression contributes to bone marrow failure in Fanconi anemia.

Authors:  Alessia Oppezzo; Julie Bourseguin; Emilie Renaud; Patrycja Pawlikowska; Filippo Rosselli
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

6.  Fanconi's anaemia: correlation of genetic complementation group with psoralen/UVA response.

Authors:  M Digweed; S Zakrzewski-Lüdcke; K Sperling
Journal:  Hum Genet       Date:  1988-01       Impact factor: 4.132

7.  Cocultivation of Fanconi anemia cells and of mouse lymphoma mutants leads to interspecies complementation of chromosomal hypersensitivity to DNA cross-linking agents.

Authors:  F Rosselli; E Moustacchi
Journal:  Hum Genet       Date:  1990-05       Impact factor: 4.132

8.  Fanconi anemia mutation causes cellular susceptibility to ambient oxygen.

Authors:  D Schindler; H Hoehn
Journal:  Am J Hum Genet       Date:  1988-10       Impact factor: 11.025

9.  Endogenous blockage and delay of the chromosome cycle despite normal recruitment and growth phase explain poor proliferation and frequent edomitosis in Fanconi anemia cells.

Authors:  M Kubbies; D Schindler; H Hoehn; A Schinzel; P S Rabinovitch
Journal:  Am J Hum Genet       Date:  1985-09       Impact factor: 11.025

10.  Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier.

Authors:  Stephen G Grant; Rubina Das; Christina M Cerceo; Wendy S Rubinstein; Jean J Latimer
Journal:  Pathol Oncol Res       Date:  2007-12-25       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.